OncoMed: Clinical Trial Update (OncoMed) - Jul 17, 2015 - “Vantictumab is well tolerated, Further dose escalation is ongoing”; “Vantictumab clearance is dose-dependent, consistent with target-mediated disposition”; “Vantictumab has pharmacodynamic (PD) effects on hair follicles, PD effects are consistent with Wnt biology, PD effects extend beyond serum exposure”; “Target efficacious dose was reached at dose level of 10 mg/kg every three weeks, Cmax is PK driver of efficacy n nonclinical efficacy models” “Vantictumab has PD effects on bone, as evidenced by β-CTX increases, Cmin (or time above a certain threshold appears to be the PK driver of toxicity”; “Increased bone turnover can be safely managed through careful monitoring, prophylactic Vitamin D and calcium supplements, and administration of zoledronic acid, if indicated”; “Prolonged stable disease...
P1 data • Oncology
|